Article Text

This article has a correction. Please see:

Download PDFPDF
Synovial synoviolin in relation to response to TNF blockade in patients with rheumatoid arthritis and psoriatic arthritis
  1. R Klaasen,
  2. C A Wijbrandts,
  3. A W van Kuijk,
  4. D Pots,
  5. D M Gerlag,
  6. P P Tak
  1. Department of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands
  1. Correspondence to Professor Paul P Tak, Division of Clinical Immunology and Rheumatology, Room F4-105, Academic Medical Center/University of Amsterdam Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands; p.p.tak{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Recently, synoviolin, a novel E3 ubiquitin ligase, was identified in rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) and synovial tissue, where it may contribute to the dysregulated proliferation and apoptosis seen in RA.1 2 Synoviolin expression is also associated with arthritis development in mice.1 The exact mechanism of synoviolin regulation and expression remains to be elucidated, but recently a role for tumour necrosis factor α (TNFα) and interleukin 1b was suggested as these cytokines increased the expression of synoviolin in RA FLS.3 Another interesting observation is that high level sustained expression of synoviolin in whole peripheral blood was related to decreased clinical response in RA patients treated with TNF blockade.4 Therefore, we investigated synoviolin expression in synovium and its relationship to later response to TNF blockade in patients with RA compared with psoriatic arthritis (PsA) and osteoarthritis (OA).

Synovial tissue samples were obtained …

View Full Text


  • Funding This study was funded by a Health Care Efficiency Research Programme.

  • Competing interests None.

  • Ethics approval Ethics approval was granted by the Medical Ethics Committee of the Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands. All patients gave written informed consent according to the declaration of Helsinki.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Linked Articles

  • Miscellaneous
    BMJ Publishing Group Ltd and European League Against Rheumatism